@article{JTD31970,
author = {Vishal Parikh and Anju Bhardwaj and Ajith Nair},
title = {Pharmacotherapy for pulmonary arterial hypertension},
journal = {Journal of Thoracic Disease},
volume = {11},
number = {Suppl 14},
year = {2019},
keywords = {},
abstract = {Pulmonary arterial hypertension (PAH) is a condition associated with substantial morbidity and mortality. Over the last 25 years there has been a significant evolution in the therapies to treat PAH. These therapies are effective for patients with group I PAH and group IV PH [chronic thromboembolic pulmonary hypertension (CTEPH)]. PAH is characterized by an imbalance of nitric oxide, prostacyclin and endothelin levels, and current pharmacotherapy involves these three pathways. Earlier clinical trials involving PAH-specific therapies evaluated improvements in 6-minute walk time as a primary improvement whereas contemporary trials have been larger and focused on morbidity and mortality reductions. While there may be a role for monotherapy in disease management, most patients should be considered for dual or triple therapy.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/31970}
}